Cardiac substructure dose and the risk of arrhythmia after curative radiotherapy for thymic tumors.

Authors

Ting-Fong Liu, Feng-Ming Hsu, Wen-Chi Yang, Yu-Sen Huang, Li-Ting Ho, Jenny Ling-Yu Chen

Published in

International journal of radiation biology. Pages 1-11. Jun 24, 2026. Epub Jun 24, 2026.

Abstract

Radiotherapy (RT) for thymic tumors often involves cardiac exposure. We evaluated the association between cardiac substructure dosimetry and post-RT arrhythmia.
This retrospective study included patients with thymic cancer or thymoma who underwent curative-intent radiotherapy between 2016 and 2024 and had available treatment plans. Cardiac substructures were auto-contoured, and mean doses, V5_Gy, and V30_Gy were calculated. Receiver operating characteristic curve analysis identified cutoff values for cardiac substructure dosimetric parameters. Univariate and multivariate analyses were performed using a competing risk model.
Among 100 patients (median follow-up, 47 months), 19 (19%) developed substantial arrhythmic events after thoracic radiotherapy. The 1-, 2-, and 5-year cumulative incidences of arrhythmia, adjusted for the competing risk of death, were 5.1%, 8.9%, and 24.4%, respectively. Patients with arrhythmic events had higher baseline World Health Organization (WHO) cardiovascular disease (CVD) risk scores and higher cardiac doses, including mean whole-heart, left atrium, left ventricle, and right ventricle doses. Receiver operating characteristic curve analysis identified predictors of arrhythmia: WHO CVD risk score > 6%, mean whole-heart dose > 2594 cGy, mean left atrium dose > 2388 cGy, mean left ventricle dose > 730 cGy, and mean right ventricle dose > 1236 cGy. In multivariate analysis, WHO CVD risk score and mean whole-heart dose remained independent predictors of arrhythmic events.
Substantial arrhythmic events after radiotherapy for thymic cancer or thymoma were associated with the baseline WHO CVD risk score and mean whole-heart dose. Implementing stricter cardiac dose constraints is essential to mitigate long-term toxicity in this potentially long-surviving cohort.

PMID:
42341211
Bibliographic data and abstract were imported from PubMed on 25 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.